Skip to main content

Hodgkin's Disease

6
Pipeline Programs
10
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
267%
Monoclonal Antibody
133%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Ono Pharmaceutical
Ono PharmaceuticalJapan - Osaka
1 program
1
NivolumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT03138499Terminated23Est. Feb 2021
Prevail Therapeutics
2 programs
1
1
R-mabHDPhase 2
PrednisonePhase 1/2
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
I-131 Tositumomab therapeutic regimenPhase 1/2
MSD
MSDIreland - Ballydine
1 program
1
VorinostatPhase 1Small Molecule1 trial
Active Trials
NCT00691210Completed40Est. Mar 2015
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
VorinostatPhase 1Small Molecule
Bristol Myers Squibb
3 programs
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology PracticesN/A1 trial
MDX-060PHASE_21 trial
R-mabHDPHASE_22 trials
Active Trials
NCT02856646Completed290Est. Sep 2020
NCT00284804Completed74Est. Oct 2009
NCT00797472Unknown120Est. Apr 2014
+1 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
TamoxifenN/A1 trial
Active Trials
NCT00165308Completed29Est. Jun 2009
GSK
GSKLONDON, United Kingdom
1 program
I-131 Tositumomab therapeutic regimenPHASE_1_21 trial
Active Trials
NCT00484874Completed12Est. Nov 2015
Chugai Pharma
Chugai PharmaJapan - Tokyo
1 program
lenograstimPHASE_2_31 trial
Active Trials
NCT01085058Completed169Est. Dec 2004

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ono PharmaceuticalNivolumab
Bristol Myers SquibbR-mabHD
Chugai Pharmalenograstim
Bristol Myers SquibbR-mabHD
Bristol Myers SquibbMDX-060
GSKI-131 Tositumomab therapeutic regimen
MSDVorinostat
Bristol Myers SquibbHodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
AstraZenecaTamoxifen

Clinical Trials (9)

Total enrollment: 1,957 patients across 9 trials

NCT03138499Ono PharmaceuticalNivolumab

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Start: Jun 2017Est. completion: Feb 202123 patients
Phase 3Terminated
NCT00816959Bristol Myers SquibbR-mabHD

Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma

Start: Jul 2011Est. completion: Apr 20141,200 patients
Phase 3Unknown
NCT01085058Chugai Pharmalenograstim

Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy

Start: May 2003Est. completion: Dec 2004169 patients
Phase 2/3Completed
NCT00797472Bristol Myers SquibbR-mabHD

Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease

Start: Jul 2011Est. completion: Apr 2014120 patients
Phase 2Unknown
NCT00284804Bristol Myers SquibbMDX-060

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Start: Nov 2005Est. completion: Oct 200974 patients
Phase 2Completed
NCT00484874GSKI-131 Tositumomab therapeutic regimen

Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Start: Jun 2007Est. completion: Nov 201512 patients
Phase 1/2Completed
NCT00691210MSDVorinostat

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Start: Jun 2008Est. completion: Mar 201540 patients
Phase 1Completed
NCT02856646Bristol Myers SquibbHodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Start: Oct 2016Est. completion: Sep 2020290 patients
N/ACompleted
NCT00165308AstraZenecaTamoxifen

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

Start: Apr 2001Est. completion: Jun 200929 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.